These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17392304

  • 21. Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects.
    Joguparthi V, Breen P, Compadre C, Zhou X, Gann L, Hiller FC, Anderson P.
    J Aerosol Med; 2003; 16(1):47-53. PubMed ID: 12737684
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ, Houghton CM, Singh SD.
    Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. FDA approves new inhaler without CFCs.
    FDA Consum; 2001; 35(4):3. PubMed ID: 11692883
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study.
    Jantikar A, Brashier B, Maganji M, Raghupathy A, Mahadik P, Gokhale P, Gogtay J, Salvi S.
    Respir Med; 2007 Apr; 101(4):845-9. PubMed ID: 17276051
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D, Vicaut E, Lefrançois G, Formoterol HFA group.
    Respiration; 2005 Apr; 72 Suppl 1():20-7. PubMed ID: 15915009
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial.
    Berger WE, Milgrom H, Skoner DP, Tripp K, Parsey MV, Baumgartner RA, Xopenex Pediatric Asthma Group.
    Curr Med Res Opin; 2006 Jun; 22(6):1217-26. PubMed ID: 16846555
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.